Nanotechnology approaches to pulmonary drug delivery

Nanostructures for drug delivery in respiratory diseases therapeutics: Revision of current trends and its comparative analysis

“…Multiple properties of nanostructures can be enhanced such as stability, accumulation, and penetration into target tissues and the ability to sort biological barriers [ 191 , 192 ]. Inhalation route for DDS delivery presents a significantly lower clearance rate for nanoparticles when compared with intravenous or oral administration routes, this is because particles administered by inhalation avoids the first-pass metabolism, resulting in increased bioavailability of the drug and extended circulation time of the nanoparticles [ 193 ]. Despite the advantages, different biological barriers must be circumvented to successfully deliver the drug into the desired action site, which can be a specific lung section or specific cell type.…”

Design and Characterization of Spray-Dried Proliposomes for the Pulmonary Delivery of Curcumin

“…45 More specifically, formulations with particle size ranging between 100 and 200 nm were proven more effective for lung administration and imposed fewer systemic side effects. 46 Furthermore, particles smaller than 200 nm can avert detection by alveolar macrophages and thus avoid rapid clearance. 47 By referring to Table 1, it is evident that formulations SD/P1, SD/P3, SD/P9, SD/P11, SD/P17 and SD/P19 prepared using lower amounts of the carrier (0.5 g) produced significantly (P < 0.05) larger PS values > 600 nm compared to their counterparts prepared using larger amounts of the carrier (1 g).…”

Nanotechnology and COVID-19: Potential Application for Treatment Sona Talaei, Hassan Mellatyar, Shiva Mohammadi, Yunes Panahi, Parisa Kianpour, Abolfazl Akbarzadeh, Nosratollah Zarghami

“…Local delivery of therapeutics to lungs has many advantages as it improves the efficiency of the treatment by enhanced accumulation of therapeutics in the lungs, also, reduces systemic side-effects of drugs on other tissues and organs through reduction of required dosage of delivered drugs and prevention of their penetration into the systemic circulation (43).…”

“…Liposomes possess properties like capacity to incorporate of drugs in core or within their membrane bilayer, ability to decrease toxicity of drugs and change their pharmacokinetics, and potential for sustained release of drugs to increase their effect over an extended time period, which make them attractive drug nanocarriers for the treatment of pulmonary infections (60,61). Liposomal DDS using both lipophilic and hydrophilic drugs was used to treatment of lung infections through the inhalation route (43). So far, liposome has been one of the most promising nanocarriers to pulmonary antibiotics delivery, with several antibiotic formulations in clinical trials (44).…”